Metabolic Alteration and Amyotrophic Lateral Scler... - BV FAPESP
Advanced search
Start date
Betweenand
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

Metabolic Alteration and Amyotrophic Lateral Sclerosis Outcome: A Systematic Review

Full text
Author(s):
Brito, Mariana Dutra [1] ; Gomes da Silva, Gustavo Ferro [1] ; Tilieri, Erick Mutti [1] ; Araujo, Beatriz Grisolia [1] ; Calio, Michele Longoni [2] ; Rosenstock, Tatiana Rosado [1]
Total Authors: 6
Affiliation:
[1] Santa Casa Sao Paulo Sch Med Sci, Dept Physiol Sci, Sao Paulo, SP - Brazil
[2] Univ Fed Sao Paulo, Dept Physiol, Sao Paulo, SP - Brazil
Total Affiliations: 2
Document type: Review article
Source: FRONTIERS IN NEUROLOGY; v. 10, NOV 20 2019.
Web of Science Citations: 0
Abstract

Background: The development of strategies that could not only efficiently detect the onset of Amyotrophic Lateral Sclerosis (ALS), a fatal neurodegenerative disorder with no cure but also predict its development and evaluate therapeutic intervention would be of great value. In this respect, the metabolic status of ALS patients has called attention. Hence, this study aimed to investigate the potential correlation between changes in ALS's metabolic parameters with the disease outcome in a systematic review. Methods: The manuscripts were manually searched within different databases (PubMed, Web of Science and Cochrane). The inclusion criteria were original articles and reviews about individuals with ALS and its survival, disease prognosis and metabolism (weight, cholesterol, hypertension, BMI, and glycaemia). The authors also established three different exclusion criteria: studies including ALS and other degenerative disorders, works including animal models and published before the year 2000. Results: In total, 29 papers were selected. From all manuscripts, only 82.8% ensured the participation of sALS patients. Also, 27.6% of selected studies described the presence of a genetic mutation. Regarding ALS prognosis, patient's age, the age of ALS onset, ALS duration and survival, <50% of the papers addressed these issues. Specifically, regarding metabolism, 65.5% of articles mentioned BMI, 20.7% mentioned any data concerning hypertension, 6.89% cardiovascular risk, 10.3% obesity, 13.78% diabetes and 10.3% glycaemia. Concerning lipid metabolism, more results were gathered, but still, they did not suffice to establish a correlation with ALS development. Conclusions: Altogether, the authors concluded that available information is not enough to establish a link between ALS and metabolism. In reality, less than half of the manuscripts evaluated show an association between both factors. Nonetheless, it is worth mentioning that metabolism does influence ALS, but not in a unique manner. There is a debate about patients' hypo- and hypermetabolism. Thus, to provide a reliable record, a public policy in which all research and clinical centers might assess the parameters discussed herein is suggested. Accordingly, this systematic review attempts to provide a comprehensible database to facilitate multicentered collaboration, validation, and clinical translation. (AU)

FAPESP's process: 15/02041-1 - The role of lysine(K)-deacetylases on mitochondrial disorders's neuroprotection: perspectives of epigenetic therapy for amyotrophic lateral sclerosis and schizophrenia
Grantee:Tatiana Rosado Rosenstock
Support Opportunities: Research Grants - Young Investigators Grants
FAPESP's process: 16/12039-7 - Lysine(K)-deacetylases modulation and its role in mitochondrial metabolism, dynamics and degradation: possible neuroprotection for amyotrophic lateral sclerosis
Grantee:Mariana Dutra Brito
Support Opportunities: Scholarships in Brazil - Master
FAPESP's process: 18/09084-6 - Functional studies in lymphocytes from Amyotrophic Lateral Sclerosis patients: relevance to biomarkers determination
Grantee:Beatriz Grisolia Araujo
Support Opportunities: Scholarships in Brazil - Scientific Initiation